Abstract Number: 1579 • ACR Convergence 2020
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…Abstract Number: 1758 • 2019 ACR/ARP Annual Meeting
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Background/Purpose: Studies have shown that anti-citrullinated protein antibodies (ACPA) are a risk factor for the development of arthritis. We aimed to investigate in a prospective…Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…Abstract Number: 605 • 2012 ACR/ARHP Annual Meeting
Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune…
- « Previous Page
- 1
- …
- 6
- 7
- 8